Patents by Inventor Anneli NORDQVIST

Anneli NORDQVIST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20240101549
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 28, 2024
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
  • N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
    Patent number: 11858924
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Grant
    Filed: June 12, 2023
    Date of Patent: January 2, 2024
    Assignee: AstraZeneca
    Inventors: Jonas Brånalt, Maria Johansson, Anneli Nordqvist, Marianne Swanson
  • N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
    Publication number: 20230406840
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R2, R3, R5, R6, R7, and R8 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: June 20, 2023
    Publication date: December 21, 2023
    Inventors: Jonas BRÅNALT, Maria JOHANSSON, Anneli NORDQVIST, Gavin O'MAHONY, Marianne SWANSON
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20230312550
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 5, 2023
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG